BlossomHill (BLSM) Director John P. Schmid Buys 6,000 Shares

What Happened

• John P. Schmid, a director of BlossomHill Therapeutics, purchased 6,000 shares on August 10, 2026, at $16.00 per share, for a total cost of $96,000. The Form 4 lists the transaction code "P" (open market or private purchase), indicating a direct buy rather than a sale or option exercise. Purchases are often viewed as more informative than sales, though this is a modest-sized insider purchase.

Key Details

• Transaction date and price: 2026-08-10; 6,000 shares @ $16.00 each.
• Total value: $96,000.
• Transaction code: P (purchase — open market or private purchase as reported).
• Shares owned after transaction: not specified in the details provided here (check the full Form 4 for post-transaction ownership).
• Footnotes / plans: no 10b5-1 plan, tax withholding, or other special footnotes indicated in the summary provided.
• Filing timeliness: Form was filed with a reporting date of 2026-08-10 and appears to have been filed promptly.

Context

• Insider purchases can signal confidence from company insiders but do not guarantee future stock performance. This single, modest purchase ($96K) is a useful data point but should be weighed with other insider activity and company fundamentals. For complete ownership impact and any later disclosures, review the full Form 4 on the SEC EDGAR site.